Table 2.
Predictors of overall survival in the 902 patients who received nivolumab enrolled in the IFCT 1502-CLINIVO study
| Cox model for OS |
||||||||
|---|---|---|---|---|---|---|---|---|
| Univariate model |
Multivariate model |
|||||||
| Factors | n | HR | 95% CI | P | HR | 95% CI | P | |
| Gender | Female | 272 | 1.000 | |||||
| Male | 630 | 0.919 | (0.79-1.07) | 0.2780 | ||||
| Age class I | LT70y | 670 | 1.000 | |||||
| GTE70y | 232 | 0.993 | (0.85-1.17) | 0.9347 | ||||
| Smoking | No | 106 | 1.000 | |||||
| Yes | 795 | 0.909 | (0.73-1.13) | 0.3972 | ||||
| PS class | LT2 | 723 | 1.000 | 1.000 | ||||
| GTE2 | 170 | 2.165 | (1.81-2.59) | <0.0001 | 2.048 | (1.69-2.47) | <0.0001 | |
| Histology | NSCC | 585 | 1.000 | 1.000 | ||||
| SCC | 317 | 1.124 | (0.97-1.30) | 0.1187 | 1.234 | (1.05-1.45) | 0.0120 | |
| Brain metastasis | No | 705 | 1.000 | 1.000 | ||||
| Yes | 197 | 1.216 | (1.03-1.44) | 0.0243 | 1.229 | (1.02-1.48) | 0.0278 | |
| Liver metastasis | No | 600 | 1.000 | 1.000 | ||||
| Yes | 212 | 1.640 | (1.39-1.94) | <0.0001 | 1.585 | (1.34-1.88) | <0.0001 | |
| Bone metastasis | No | 508 | 1.000 | 1.000 | ||||
| Yes | 305 | 1.292 | (1.11-1.51) | 0.0010 | 1.257 | (1.07-1.47) | 0.0044 | |
| Steroid administration | No | 817 | 1.000 | 1.000 | ||||
| Yes | 81 | 1.519 | (1.19-1.93) | 0.0006 | 1.175 | (0.91-1.52) | 0.2135 | |
CI, confidence interval; GTE, greater than or equal; HR, hazard ratio; IFCT, French Cooperative Thoracic Intergroup; LT, lower than; NSCC, non-squamous cell carcinoma; OS, overall survival; PS, performance status; SCC, squamous cell carcinoma.